Corrigendum: Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential.

SPR binding kinetics drug development lead optimization male contraceptive picomolar potency residence time soluble adenylyl cyclase

Journal

Frontiers in physiology
ISSN: 1664-042X
Titre abrégé: Front Physiol
Pays: Switzerland
ID NLM: 101549006

Informations de publication

Date de publication:
2023
Historique:
received: 10 02 2023
accepted: 21 02 2023
entrez: 23 3 2023
pubmed: 24 3 2023
medline: 24 3 2023
Statut: epublish

Résumé

[This corrects the article DOI: 10.3389/fphys.2022.1013845.].

Identifiants

pubmed: 36950298
doi: 10.3389/fphys.2023.1163389
pii: 1163389
pmc: PMC10027417
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

1163389

Commentaires et corrections

Type : ErratumFor

Informations de copyright

Copyright © 2023 Rossetti, Ferreira, Ghanem, Buck, Steegborn, Myers, Meinke, Levin and Buck.

Auteurs

Thomas Rossetti (T)

Department of Pharmacology, Weill Cornell Medicine, New York, NY, United States.

Jacob Ferreira (J)

Department of Pharmacology, Weill Cornell Medicine, New York, NY, United States.

Lubna Ghanem (L)

Department of Pharmacology, Weill Cornell Medicine, New York, NY, United States.

Hannes Buck (H)

Department of Pharmacology, Weill Cornell Medicine, New York, NY, United States.

Clemens Steegborn (C)

Department of Biochemistry, University of Bayreuth, Bayreuth, Germany.

Robert W Myers (RW)

Tri-Institutional Therapeutics Discovery Institute, New York, NY, United States.

Peter T Meinke (PT)

Tri-Institutional Therapeutics Discovery Institute, New York, NY, United States.

Lonny R Levin (LR)

Department of Pharmacology, Weill Cornell Medicine, New York, NY, United States.

Jochen Buck (J)

Department of Pharmacology, Weill Cornell Medicine, New York, NY, United States.

Classifications MeSH